Log in

Covidien Stock Price, Forecast & Analysis (NYSE:COV)

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.04
0.00 (0.00 %)
(As of 06/7/2019)
Add
Today's Range
$0.04
Now: $0.04
$0.04
50-Day Range N/A
52-Week Range
$65.97
Now: $0.04
$108.57
VolumeN/A
Average Volume3.88 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company's brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
CUSIPG2554F11
WebN/A
Phone+353-1-4381700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive COV News and Ratings via Email

Sign-up to receive the latest news and ratings for COV and its competitors with MarketBeat's FREE daily newsletter.


Covidien (NYSE:COV) Frequently Asked Questions

What is Covidien's stock symbol?

Covidien trades on the New York Stock Exchange (NYSE) under the ticker symbol "COV."

How were Covidien's earnings last quarter?

Covidien Ltd (NYSE:COV) released its earnings results on Wednesday, November, 5th. The healthcare company reported $1.15 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.02 by $0.13. The healthcare company earned $2.73 billion during the quarter, compared to analysts' expectations of $2.69 billion. The business's quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.91 earnings per share. View Covidien's Earnings History.

Has Covidien been receiving favorable news coverage?

Media coverage about COV stock has trended somewhat positive on Thursday, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Covidien earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave news coverage about the healthcare company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Covidien.

Who are some of Covidien's key competitors?

What other stocks do shareholders of Covidien own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covidien investors own include Pfizer (PFE), Intel (INTC), Chevron (CVX), Johnson & Johnson (JNJ), Celgene (CELG), Boeing (BA), CVS Health (CVS), EMC (EMC), Gilead Sciences (GILD) and JPMorgan Chase & Co. (JPM).

Who are Covidien's key executives?

Covidien's management team includes the folowing people:
  • Gary L. Ellis, President, Chief Executive Officer (Age 61)
  • Charles J. Dockendorff, Chief Financial Officer, Executive Vice President (Age 63)
  • Bryan C. Hanson, Group President, Covidien (Age 50)
  • John H. Masterson, Senior Vice President, General Counsel (Age 54)
  • Michael P. Dunford, Senior Vice President - Human Resources (Age 54)
  • James C. Clemmer, Senior Vice President and President - Medical Supplies Business (Age 53)
  • Amy A. McBride-Wendell, Senior Vice President - Strategy and Business Development (Age 53)
  • Jacqueline F. Strayer, Senior Vice President-Corporate Communications (Age 58)
  • Michael E. Tarnoff, Senior Vice President,Chief Medical Officer (Age 46)
  • Peter L. Wehrly, Senior Vice President, Group President - Developed Markets (Age 57)

What is Covidien's stock price today?

One share of COV stock can currently be purchased for approximately $0.04.

How can I contact Covidien?

Covidien's mailing address is 20 On Hatch Lower Hatch Street, Dublin 2, DUBLIN,, Ireland. The healthcare company can be reached via phone at +353-1-4381700.


MarketBeat Community Rating for Covidien (NYSE COV)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  399 (Vote Outperform)
Underperform Votes:  248 (Vote Underperform)
Total Votes:  647
MarketBeat's community ratings are surveys of what our community members think about Covidien and other stocks. Vote "Outperform" if you believe COV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/5/2019 by MarketBeat.com Staff

Featured Article: Return on Equity (ROE)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel